Treatment of Minimal Residual Disease in “Poor Risk” Acute Lymphoblastic Leukaemia with High-Dose Cytosine Arabinoside
The recognition of adverse prognostic factors has allowed the identification of patients with acute lymphoblastic leukaemia (ALL) in whom, although complete remission (CR) is achieved, bone marrow relapse is likely to occur (1,2). There is evidence to suggest that intensification of initial therapy may reduce the frequency of relapse in such “poor risk” patients (3,4).
KeywordsComplete Remission Acute Lymphoblastic Leukemia Minimal Residual Disease Acute Lymphoblastic Leukaemia Cytosine Arabinoside
Unable to display preview. Download preview PDF.
- 2.Barnett MJ et al: Treatment of acute lymphoblastic leukaemia in adults. (Submitted for publication)Google Scholar
- 3.Henze G et al: Treatment strategy for different risk groups in childhood acute lymphoblastic leukemia. In Modern Trends in Human Leukemia IV:87–93 (1981)Google Scholar
- 5.Barnett MJ et al: A phase II study of high-dose cytosine arabinoside in the treatment of acute non-myelogenous leukaemia. (In preparation)Google Scholar